Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 27, 2017

Study Completion Date

December 31, 2021

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

CF102

orally q12h

DRUG

Placebo

orally q12 hours

Trial Locations (21)

75390

Simmons Cancer Center, Dallas

80045

University of Colorado Cancer Center, Aurora

Unknown

Complex Oncology Center - Plovdiv, Plovdiv

Multiprofile Hospital for Active Treatment Central Onco Hospita, Plovdiv

"Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia AD", Sofia

Multiprofile Hospital for Active Treatment for women's health - Nadezhda, Sofia

Multiprofile Hospital for Active Treatment Serdica, Sofia

"Multiprofile Hospital for Active Treatment Sveta Marina EAD", Varna

Rabin Medical Center, Petah Tikva

Institutul Clinic Fundeni - Sectia Oncologie Medicala, Bucharest

Clinica Bendis - Oncologie Medicala, Cluj-Napoca

Centrul de Oncologie ONCOLAB, Craiova

Institutul Regional de Oncologie Iasi - Sectia Oncologie Medicala, Iași

Spitalul Pelican Impex SRL- Sectia Oncologie Medicala, Oradea

SC DACMED SRL - Oncologie, Ploieşti

Spitalului Clinic Judetean de Urgenta - Sectia Oncologie Medicala, Sibiu

"Spitalul Judetean de Urgenta Sf. Ioan Cel Nou - sectia Oncologie Medicala", Suceava

Vojnomedicinska Akademija Beograd, Belgrade

Institut za Onkologiju Vojvodine, Kamenitz

Zdravstveni Centar Kladovo Služba Onkologije, Kladovo

Klinički Centar Niš Klinika za Onkologiju, Niš

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Can-Fite BioPharma

INDUSTRY

NCT02128958 - Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter